Navigation Links
Can gene therapy cure fatal diseases in children?
Date:9/5/2012

In order for the body to function, a balance is necessary between the cells that build up the bones in our skeletons and the cells that break them down. In the disease malignant infantile osteopetrosis, MIOP, the cells that break down the bone tissue do not function as they should, resulting in the skeleton not having sufficient cavities for bone-marrow and nerves.

"Optic and auditory nerves are compressed, causing blindness and deafness in these children. Finally the bone marrow ceases to function and, without treatment, the child dies of anaemia and infections", explains Carmen Flores Bjurstrm. She has just completed a thesis which presents some of the research at the division for Molecular Medicine and Gene Therapy in Lund.

The researchers' work focuses on finding alternatives to the only treatment currently available against MIOP, namely a bone-marrow transplant. This treatment can be effective, but it is both risky and dependent on finding a suitable donor.

Gene therapy requires no donor, as stem cells are taken from the patients themselves. Once the cells' non-functioning gene has been replaced with a healthy copy of itself, the stem cells are put back into the patient.

Great hopes have been placed on gene therapy as a treatment method but the work has proven to be more difficult than expected. The method is used today for certain immunodeficiency diseases, and has also been applied to a blood disorder called thalassemia.

"So far, the method is not risk-free. Since it is impossible to control where the introduced gene ends up, there is a certain risk of it ending up in the wrong place and giving rise to leukaemia. This is why gene therapy is only used for serious diseases for which there is no good treatment", says Carmen Flores Bjurstrm.

The Lund researchers have conducted experiments with gene therapy in both patient cells and laboratory animals. The next step is to conduct trials on patients. The trials will probably take place at the hospital in Ulm, Germany, which currently treats the majority of children in Europe suffering from MIOP.

MIOP is a rare disease: in Sweden a child is born with the condition approximately once every three years. Worldwide, the incidence of the disease is one case for every 300 000 births. It is, however, more common in Costa Rica where 3-4 children per 100 000 births have the disease.

"But there are several other genetic mutations that lead to other osteopetrosis diseases. If we manage to treat MIOP, it may become possible to treat these other conditions as well", hopes Carmen Flores Bjurstrm along with her supervisor, Professor Johan Richter.


'/>"/>
Contact: Carmen Flores Bjurstrm
carmen.flores@med.lu.se
0046-462-220-590
Lund University
Source:Eurekalert

Related medicine news :

1. KRAS gene mutation and amplification status affects sensitivity to antifolate therapy
2. Antibody therapy prevents gastrointestinal damage following radiation exposure in mice
3. Chemotherapy proves life-saving for some leukemia patients who fail induction therapy
4. Immunotherapy for elderly cancer patients finds new promise in drug combination
5. Therapy exploits addiction of leukemia cells
6. Intensity Modulated Radiation Therapy optimal for localized prostate cancer
7. Adding drug to standard chemotherapy provides no survival benefit for older lung cancer patients
8. Study Casts Doubt on Value of Pricey Prostate Cancer Therapy
9. 19th century therapy for Parkinsons disease may help patients today
10. New Psoriasis Drugs Not Much Better Than Standard Therapy, Study Finds
11. Xenotransplantation as a therapy for type 1 diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... ... Delaware farmer Rick Dickerson attended the 2017 Soybean Leadership College ... a thousand acres of soybeans, corn and wheat, and raises peas, sweet corn, baby ... for the fresh market. He also operates a roadside stand and raises broilers for ...
(Date:1/18/2017)... FORT LAUDERDALE, FL (PRWEB) , ... January 18, ... ... and how to manage it from the number one doctor-recommended OTC antiperspirant, Certain ... population and often go untreated. , Certain Dri created this infographic to explain ...
(Date:1/18/2017)... ARBOR, Mich. USA; SAN JOSE, Calif, USA; and SHANGHAI, China ... ... (PRWEB) January 18, 2017 -- Global public health ... to reduce arsenic V (pentavalent arsenic) to NSF/ANSI 53: Drinking ... for drinking water treatment units. This certification verifies that MicroCeramics’ ...
(Date:1/18/2017)... ... January 18, 2017 , ... The V Foundation for Cancer Research, ... official endurance training and fundraising team, to compete in the Boston Marathon on April ... to finish the world’s oldest annual marathon to join Team V and support the ...
(Date:1/18/2017)... , ... January 18, 2017 , ... ... announce that their Vice President of Franchise Development, Paula Turner Pizarro, was recently ... business program, which features the insights of top business leaders from across the ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... 2017  EnteroMedics Inc. (NASDAQ: ETRM ... technology to treat obesity, metabolic diseases and other ... underwritten public offering of units for gross proceeds ... and commissions and offering expenses payable by EnteroMedics. ... A Units, priced at a public offering price ...
(Date:1/18/2017)...  Adaptive Sound Technologies, Inc. (ASTI), the leading supplier ... Hyatt Place Nashville/Downtown to deliver the best sleep experience ... machines in over two hundred of its guest rooms. ... of having a great stay is sleeping well," said ... Nashville/Downtown. "We,re pleased to be able to offer our ...
(Date:1/18/2017)... 18, 2017  Dermata Therapeutics, LLC, a biotechnology ... a variety of dermatological diseases, announces dosing the ... a Phase 2 acne rosacea study. DMT210 is ... proinflammatory cytokines in the skin responsible for the ... This clinical trial, DMT210-003, is a ...
Breaking Medicine Technology: